Biomedical papers, 2016 (vol. 160), issue 1

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016, 160(1):11-19 | 10.5507/bp.2015.046

Chemical inhibition of DNA repair kinases as a promising tool in oncology

Kamila Durisova, Barbora Salovska, Jaroslav Pejchal, Ales Tichy
Department of Radiobiology, Faculty of Military Health Sciences in Hradec Kralove, University of Defence in Brno, Czech Republic

Background: DNA repair pathways play a major role in tumour resistance towards chemo- and radiotherapy. Therefore, inhibitors of specific DNA repair pathways might be advantageous when used in combination with DNA-damaging agents, such as ionizing radiation. This review put particular emphasis on the key DNA repair enzymes: DNA-dependent protein kinase (DNA-PK), ataxia-telangiectasia mutated kinase (ATM) and ATM-Rad3-related kinase (ATR) and their specific inhibitors in the context of radio-sensitization.

Results: We reviewed recent studies on novel and potent inhibitors and found evidence that inhibitors of DNA repair pathways such as small molecule inhibitors could be efficient and selective in tumour cells. Interpretation of recent literature results accompanied with implications for practice and further research are presented.

Conclusions: The prospects of targeting DNA repair enzymes to treat cancer are optimistic, but future work will show if this approach has a significant in vivo efficacy, since we are still waiting for the inhibitor which would pass all phases in clinical trials. In spite of the fact that a number of drugs possess interesting synergy of radiotherapy in vitro, the future use will depend on developing compounds with improved solubility and the serum half-life. Normal tissue toxicity leading to a significant increase of radiotherapy efficiency remains a key question that might be answered only by clinical trials.

Keywords: DNA repair; inhibitor; DNA-PK; ATM; ATR; ionising radiation

Received: November 12, 2014; Accepted: September 10, 2015; Prepublished online: October 21, 2015; Published: March 30, 2016


References

  1. Guirouilh-Barbat J, Huck S, Bertrand P, Pirzio L, Desmaze C, Sabatier L, Lopez BS. Impact of the KU80 Pathway on NHEJ-Induced Genome Rearrangements in Mammalian Cells. Molecular Cell 2004;14(5):611-23. Go to original source... Go to PubMed...
  2. Mao Z, Bozzella M, Seluanov A, Gorbunova V. DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle 2008;7(18):2902-6. Go to original source... Go to PubMed...
  3. Goodwin CB, Yang Z, Yin F, Yu M, Chan RJ. Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. Haematologica 2012;97(7):1042-7. Go to original source... Go to PubMed...
  4. Shang Z-F, Huang B, Xu Q-Z, Zhang S-M, Fan R, Liu X-D, Wang Y, Zhou P-K. Inactivation of DNA-dependent protein kinase leads to spindle disruption and mitotic catastrophe with attenuated checkpoint protein 2 Phosphorylation in response to DNA damage. Cancer Res 2010;70(9):3657-66. Go to original source... Go to PubMed...
  5. Rothkamm K, Krüger I, Thompson LH, Löbrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003;23(16):5706-15. Go to original source... Go to PubMed...
  6. Bannister LA, Waldman BC, Waldman AS. Modulation of error-prone double-strand break repair in mammalian chromosomes by DNA mismatch repair protein Mlh1. DNA Repair 2004;3(5):465-74. Go to original source... Go to PubMed...
  7. Grabarz A, Barascu A, Guirouilh-Barbat J, Lopez BS. Initiation of DNA double strand break repair: signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end-joining. Am J Cancer Res 2012;2(3):249-68. Go to PubMed...
  8. Parsons CA, Baumann P, Van Dyck E, West SC. Precise binding of single-stranded DNA termini by human RAD52 protein. EMBO J 2000;19(15):4175-81. Go to original source... Go to PubMed...
  9. Sugiyama T, New JH, Kowalczykowski SC. DNA annealing by Rad52 Protein is stimulated by specific interaction with the complex of replication protein A and single-stranded DNA. Proc Natl Acad Sci U S A 1998;95(11):6049-54. Go to original source... Go to PubMed...
  10. Budke B, Chan Y-L, Bishop DK, Connell PP. Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing. Nucleic Acids Res 2013;41(13):e130. Go to original source... Go to PubMed...
  11. Schwacha A, Kleckner N. Identification of double Holliday junctions as intermediates in meiotic recombination. Cell 1995;83(5):783-91. Go to original source... Go to PubMed...
  12. Holliday R. A mechanism for gene conversion in fungi. Genet Res 1964;5(02):282-304. Go to original source...
  13. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993;72(1):131-42. Go to original source... Go to PubMed...
  14. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005;434(7033):605-11. Go to original source... Go to PubMed...
  15. Mimori T, Hardin JA. Mechanism of interaction between Ku protein and DNA. J Biol Chem 1986;261(22):10375-9. Go to PubMed...
  16. Falzon M, Fewell JW, Kuff EL. EBP-80, a transcription factor closely resembling the human autoantigen Ku, recognizes single- to double-strand transitions in DNA. J Biol Chem 1993;268(14):10546-52. Go to PubMed...
  17. Blier PR, Griffith AJ, Craft J, Hardin JA. Binding of Ku protein to DNA. Measurement of affinity for ends and demonstration of binding to nicks. J Biol Chem 1993;268(10):7594-601. Go to PubMed...
  18. Douglas P, Sapkota GP, Morrice N, Yu Y, Goodarzi AA, Merkle D, Meek K, Alessi DR, Lees-Miller SP. Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase. Biochem J 2002;368(Pt 1):243-51. Go to original source... Go to PubMed...
  19. Chen BPC, Chan DW, Kobayashi J, Burma S, Asaithamby A, Morotomi-Yano K, Botvinick E, Qin J, Chen DJ. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem 2005;280(15):14709-15. Go to original source... Go to PubMed...
  20. Grawunder U, Wilm M, Wu X, Kulesza P, Wilson TE, Mann M, Lieber MR. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature 1997;388(6641):492-5. Go to original source... Go to PubMed...
  21. Kozlov SV, Graham ME, Peng C, Chen P, Robinson PJ, Lavin MF. Involvement of novel autophosphorylation sites in ATM activation. EMBO J 2006;25(15):3504-14. Go to original source... Go to PubMed...
  22. Tomita M. Involvement of DNA-PK and ATM in radiation- and heat-induced DNA damage recognition and apoptotic cell death. J Radiat Res 2010;51(5):493-501. Go to original source... Go to PubMed...
  23. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000;60(21):5934-6. Go to PubMed...
  24. Lopez-Girona A, Tanaka K, Chen XB, Baber BA, McGowan CH, Russell P. Serine-345 is required for Rad3-dependent phosphorylation and function of checkpoint kinase Chk1 in fission yeast. Proc Natl Acad Sci USA 2001;98(20):11289-94. Go to original source... Go to PubMed...
  25. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14(12):1448-59. Go to PubMed...
  26. Hurley PJ, Bunz F. ATM and ATR: components of an integrated circuit. Cell Cycle 2007;6(4):414-7. Go to original source... Go to PubMed...
  27. MacMillan J, Vanstone AE, Yeboah SK. The structure of wortmannin, a steroidal fungal metabolite. Chem Commun (London) 1968;(11):613-4. Go to original source...
  28. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993;296(Pt 2):297-301. Go to original source... Go to PubMed...
  29. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16(4):1722-33. Go to original source... Go to PubMed...
  30. Kimura K, Hattori S, Kabuyama Y, Shizawa Y, Takayanagi J, Nakamura S, Toki S, Matsuda Y, Onodera K, Fukui Y. Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 1994;269(29):18961-7. Go to PubMed...
  31. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 1997;3(7):1149-56. Go to PubMed...
  32. Imai Y, Yamagishi H, Ono Y, Ueda Y. Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. Clin Transl Med 2012;1(1):24. Go to original source... Go to PubMed...
  33. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269(7):5241-8. Go to PubMed...
  34. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996;15(19):5256-7. Go to PubMed...
  35. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007;404(1):15-21. Go to original source... Go to PubMed...
  36. Gong C, Liao H, Wang J, Lin Y, Qi J, Qin L, Tian L-Q, Guo F-J. LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity. Asian Pac J Cancer Prev 2012;13(7):3103-7. Go to original source... Go to PubMed...
  37. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, McKenna WG. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003;56(3):846-53. Go to original source... Go to PubMed...
  38. Take Y, Kumano M, Hamano Y, Fukatsu H, Teraoka H, Nishimura S, Okuyama A. OK-1035, a Selective Inhibitor of DNA-Dependent Protein Kinase. Biochem Biophys Res Commun 1995;215(1):41-7. Go to original source... Go to PubMed...
  39. Take Y, Kumano M, Teraoka H, Nishimura S, Okuyama A. DNA-Dependent Protein Kinase Inhibitor (OK-1035) Suppresses p21 Expression in HCT116 Cells Containing Wild-Type p53 Induced by Adriamycin. Biochem Biophys Res Commun 1996;221(2):207-12. Go to original source... Go to PubMed...
  40. Stockley M, Clegg W, Fontana G, Golding BT, Martin N, Rigoreau LJ., Smith GC., Griffin RJ. Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydrazonomethyl-5-(4-pyridyl)pyrid-[1H]-2-one (OK-1035). Bioorg Med Chem Lett 2001;11(21):2837-41. Go to original source... Go to PubMed...
  41. Ismail IH, Mårtensson S, Moshinsky D, Rice A, Tang C, Howlett A, McMahon G, Hammarsten O. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 2004;23(4):873-82. Go to original source... Go to PubMed...
  42. Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, Aloyz R, Panasci L. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest New Drugs 2012;30(4):1736-42. Go to original source... Go to PubMed...
  43. Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodkinson K, Masson J-Y, Aloyz R, Panasci L. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs 2012;30(3):1248-56. Go to original source... Go to PubMed...
  44. Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, Huang H, Burgess LE, Kesicki EA, Halbrook J. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2003;2(12):1257-64. Go to PubMed...
  45. Allen C, Halbrook J, Nickoloff JA. Interactive Competition Between Homologous Recombination and Non-Homologous End Joining. Mol Cancer Res 2003;1(12):913-20. Go to PubMed...
  46. Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, Halbrook J, Kesicki EA, Kashishian A, Hallahan DE. DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation-Sensitizing Drugs. Cancer Res 2005;65(12):4987-92. Go to original source... Go to PubMed...
  47. Shinohara E, Halbrook J, Geng L, Xia F, Hallahan DE. Radiosensatization by the novel DNA-Dependent Protein Kinase (DNA-PK) inhibitors, IC87102 and IC87361 in animal tumor models. AACR Meeting Abstracts 2004;2004(1):310-a.
  48. Tamai K, Tezuka H, Kuroda Y. Different modifications by vanillin in cytotoxicity and genetic changes induced by EMS and H2O2 in cultured Chinese hamster cells. Mutat Res 1992;268(2):231-7. Go to original source... Go to PubMed...
  49. Jansson T, Zech L. Effects of vanillin on sister-chromatid exchanges and chromosome aberrations in human lymphocytes. Mutat Res 1987;190(3):221-4. Go to original source... Go to PubMed...
  50. Yaneva M, Li H, Marple T, Hasty P. Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor. Nucleic Acids Res 2005;33(16):5320-30. Go to original source... Go to PubMed...
  51. Durant S, Karran P. Vanillins-a novel family of DNA-PK inhibitors. Nucleic Acids Res 2003;31(19):5501-12. Go to original source... Go to PubMed...
  52. Leahy JJJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, Smith GCM. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 2004;14(24):6083-7. Go to original source... Go to PubMed...
  53. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu H-K, Peng Q, Durden DL. A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity. Cancer Res 2008;68(1):206-15. Go to original source... Go to PubMed...
  54. Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol 2010;65(4):697-706. Go to original source... Go to PubMed...
  55. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer 2012;48(18):3319-27. Go to original source... Go to PubMed...
  56. Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GCM, Martin NMB, Workman P, Raynaud FI. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer 2005;93(9):1011-8. Go to PubMed...
  57. You H, Kong M, Wang L, Xiao X, Liao H, Bi Z, Yan H, Wang H, Wang C, Ma Q, Liu Y, Bi Y. Inhibition of DNA-dependent protein kinase catalytic subunit by small molecule inhibitor NU7026 sensitizes human leukemic K562 cells to benzene metabolite-induced apoptosis. J Huazhong Univ Sci Technol Med Sci 2013;33(1):43-50. Go to original source... Go to PubMed...
  58. Tichý A, Novotná E, Durisová K, Salovská B, Sedlaríková R, Pejchal J, Zárybnická L, Vávrová J, Sinkorová Z, Rezácová M. Radio-sensitization of human leukaemic molt-4 cells by DNA-dependent protein kinase inhibitor, NU7026. Acta Medica (Hradec Kralove) 2012;55(2):66-73. Go to original source... Go to PubMed...
  59. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004;103(12):4659-65. Go to original source... Go to PubMed...
  60. Hardcastle IR, Cockcroft X, Curtin NJ, El-Murr MD, Leahy JJJ, Stockley M, Golding BT, Rigoreau L, Richardson C, Smith GCM, Griffin RJ. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem 2005;48(24):7829-46. Go to original source... Go to PubMed...
  61. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GCM, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66(10):5354-62. Go to original source... Go to PubMed...
  62. Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother Pharmacol 2012;69(1):155-64. Go to original source... Go to PubMed...
  63. Tsuji T, Sapinoso L, Sankar S, Mortensen DS, Xu S. 306 CC-115 inhibits DNA damage and repair pathways in vitro. In: Egermont AM, editor. European Journal of Cancer. Proceedings of the 26th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics; 2014, 18-21 November; Barcelona, Spain. Oxford: Elsevier; 2014. p. 100.
  64. Mortensen DS, Fultz KE, Xu W, Tsuji T, Hickman M, Abbasian M, Khambatta G, Cathers B, Worland P, Moghaddam MF, Apuy J, Richardson S, Elsner J, Shevlin G, Perrin-Ninkovic S, Canan S, Raymon HK, Narla RK, Peng S, Sankar S. 459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation. In: Egermont AM, editor. European Journal of Cancer. Proceedings of the 26th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics; 2014, 18-21 November; Barcelona, Spain. Oxford: Elsevier; 2014. p. 150.
  65. Chandra G, Alexander V, Lee HW, Jeong LS. Improved synthesis of a DNA-dependent protein kinase inhibitor IC86621. Arch Pharm Res 2012;35(4):639-45. Go to original source... Go to PubMed...
  66. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine. Cancer Res 1999;59(17):4375-82.
  67. Cortez D. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases. J Biol Chem 2003;278(39):37139-45. Go to original source... Go to PubMed...
  68. Blasina A, Price BD, Turenne GA, McGowan CH. Caffeine inhibits the checkpoint kinase ATM. Curr Biol 1999;9(19):1135-8. Go to original source... Go to PubMed...
  69. Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NMB, Lau A, Newell DR, Curtin NJ. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther 2013;12(6):959-67. Go to original source... Go to PubMed...
  70. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GCM. Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM. Cancer Res 2004;64(24):9152-9. Go to original source... Go to PubMed...
  71. Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GCM, Leung HY, Curtin NJ, Robson CN. Targeting the DNA double strand break repair machinery in prostate cancer. PLoS ONE 2011;6(5):e20311. Go to original source... Go to PubMed...
  72. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, O'Connor MJ, Povirk LF, van Meter T, Valerie K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 2009;8(10):2894-902. Go to original source... Go to PubMed...
  73. Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ, Valerie K. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle 2012;11(6):1167-73. Go to original source... Go to PubMed...
  74. White JS, Choi S, Bakkenist CJ. Transient ATM kinase inhibition disrupts DNA damage-induced sister chromatid exchange. Sci Signal 2010;3(124):ra44. Go to PubMed...
  75. White JS, Choi S, Bakkenist CJ. Irreversible chromosome damage accumulates rapidly in the absence of ATM kinase activity. Cell Cycle 2008;7(9):1277-84. Go to original source... Go to PubMed...
  76. Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to Ionizing Radiation. Cancer Res 2008;68(18):7466-74. Go to original source... Go to PubMed...
  77. Wang H, Zuo B, Wang H, Ren L, Yang P, Zeng M, Duan D, Liu C, Li M. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012;422(1):103-8. Go to original source... Go to PubMed...
  78. Harrison LRE, Ottley CJ, Pearson DG, Roche C, Wedge SR, Dolan ME, Newell DR, Tilby MJ. The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Biochem Pharmacol 2009;77(10):1586-92. Go to original source... Go to PubMed...
  79. Peasland A, Wang L-Z, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 2011;105(3):372-81. Go to original source... Go to PubMed...
  80. Sultana R, Abdel-Fatah T, Perry C, Moseley P, Albarakti N, Mohan V, Seedhouse C, Chan S, Madhusudan S. Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells. PLoS ONE 2013;8(2):e57098. Go to original source... Go to PubMed...
  81. Liu GT. Pharmacological actions and clinical use of fructus schizandrae. Chin Med J 1989;102(10):740-9. Go to PubMed...
  82. Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko KM, Hamamori Y, Konishi T. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucl Acids Res 2009;37(17):5678-89. Go to original source... Go to PubMed...
  83. Tatewaki N, Nishida H, Yoshida M, Ando H, Kondo S, Sakamaki T, Konishi T. Differential effect of schisandrin B stereoisomers on ATR-mediated DNA damage checkpoint signaling. J Pharmacol Sci 2013;122(2):138-48. Go to original source... Go to PubMed...
  84. Li L, Lu Q, Shen Y, Hu X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol 2006;71(5):584-95. Go to original source... Go to PubMed...
  85. Reaper PM, Griffiths MR, Long JM, Charrier J-D, Maccormick S, Charlton PA, Golec JMC, Pollard JR. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011;7(7):428-30. Go to original source... Go to PubMed...
  86. Vávrová J, Zárybnická L, Lukášová E, Řezáčová M, Novotná E, Sinkorová Z, Tichý A, Pejchal J, Durišová K. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiat Environ Biophys 2013;52(4):471-9. Go to original source... Go to PubMed...
  87. Charrier J-D, Durrant SJ, Golec JMC, Kay DP, Knegtel RMA, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM, Rutherford AP, Wang PSH, Young SC, Pollard JR. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem 2011;54(7):2320-30. Go to original source... Go to PubMed...
  88. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W, Muschel RJ, Brunner TB. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012;3:e441. Go to original source... Go to PubMed...
  89. Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, Hickson I, Jacq X, Jewsbury PJ, McGuire TM, Nissink JWM, Odedra R, Page K, Perkins P, Suleman A, Tam K, Thommes P, Broadhurst R, Wood C. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem 2013;56(5):2125-38. Go to original source... Go to PubMed...
  90. Jones CD, Blades K, Foote KM, Guichard SM, Jewsbury PJ, McGuire T, Nissink JW, Odedra R, Tam K, Thommes P, Turner P, Wilkinson G, Wood C, Yates JW. Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients. In: Prendergast GC, editor. The Journal of Cancer Research. Proceedings of the AACR 104th Annual Meeting 2013; 2013, 06-10 April; Washington DC, USA. Philadelphia: AACR; 2013. p. 2348.
  91. Pastwa E, Poplawski T, Lewandowska U, Somiari SB, Blasiak J, Somiari RI. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells. Int J Biochem Cell Biol 2014;53:423-31. Go to original source... Go to PubMed...
  92. Zhao J-X, Liu H, Lv J, Yang X-J. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro. Eur Rev Med Pharmacol Sci 2014;18(17):2428-34. Go to PubMed...
  93. Carminati PO, Donaires FS, Marques MM, Donadi EA, Passos G a. S, Sakamoto-Hojo ET. Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells. Mol Biol Rep 2014;41(1):165-77. Go to original source... Go to PubMed...
  94. Kruszewski M, Wojewódzka M, Iwaneńko T, Szumiel I, Okuyama A. Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Mutat Res 1998;409(1):31-6. Go to original source... Go to PubMed...
  95. Niazi MT, Mok G, Heravi M, Lee L, Vuong T, Aloyz R, Panasci L, Muanza T. Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87. Curr Oncol 2014;21(2):91-6. Go to original source... Go to PubMed...
  96. Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res Treat 2014;143(1):47-55. Go to original source... Go to PubMed...
  97. Tichy A, Durisova K, Salovska B, Pejchal J, Zarybnicka L, Vavrova J, Dye NA, Sinkorova Z. Radio-sensitization of human leukaemic MOLT-4 cells by DNA-dependent protein kinase inhibitor, NU7441. Radiat Environ Biophys 2014;53(1):83-92. Go to original source... Go to PubMed...
  98. Alao JP, Sunnerhagen P. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation. Radiat Oncol 2009;4(1):51. Go to original source... Go to PubMed...
  99. Cmielova J, Havelek R, Kohlerova R, Soukup T, Bruckova L, Suchanek J, Vavrova J, Mokry J, Rezacova M. The effect of ATM kinase inhibition on the initial response of human dental pulp and periodontal ligament mesenchymal stem cells to ionizing radiation. Int J Radiat Biol 2013;89(7):501-11. Go to original source... Go to PubMed...
  100. Park J, Jo YH, Cho CH, Choe W, Kang I, Baik HH, Yoon K-S. ATM-deficient human fibroblast cells are resistant to low levels of DNA double-strand break induced apoptosis and subsequently undergo drug-induced premature senescence. Biochem Biophys Res Commun 2013;430(1):429-35. Go to original source... Go to PubMed...
  101. Zhu Y, Mao C, Wu J, Li S, Ma R, Cao H, Ji M, Jing C, Tang J. Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer. Oncol Lett 2014;8(5):2043-8. Go to PubMed...
  102. Vecchio D, Daga A, Carra E, Marubbi D, Raso A, Mascelli S, Nozza P, Garrè ML, Pitto F, Ravetti JL, Vagge S, Corvò R, Profumo A, Baio G, Marcello D, Frosina G. Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019. Int J Cancer 2015;136(6):1445-57. Go to original source... Go to PubMed...
  103. Salovska B, Fabrik I, Durisova K, Link M, Vavrova J, Rezacova M, Tichy A. Radiosensitization of Human Leukemic HL-60 Cells by ATR Kinase Inhibitor (VE-821): Phosphoproteomic Analysis. Int J Mol Sci 2014;15(7):12007-26. Go to original source... Go to PubMed...
  104. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM. ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status. Cancer Res 2013;73(12):3683-91. Go to original source... Go to PubMed...